JPWO2023220109A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2023220109A5
JPWO2023220109A5 JP2024566219A JP2024566219A JPWO2023220109A5 JP WO2023220109 A5 JPWO2023220109 A5 JP WO2023220109A5 JP 2024566219 A JP2024566219 A JP 2024566219A JP 2024566219 A JP2024566219 A JP 2024566219A JP WO2023220109 A5 JPWO2023220109 A5 JP WO2023220109A5
Authority
JP
Japan
Prior art keywords
composition
fluoro
amount
dimethyloxan
oxoimidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024566219A
Other languages
English (en)
Japanese (ja)
Other versions
JP7767651B2 (ja
JP2025515706A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/021637 external-priority patent/WO2023220109A1/en
Publication of JP2025515706A publication Critical patent/JP2025515706A/ja
Publication of JPWO2023220109A5 publication Critical patent/JPWO2023220109A5/ja
Application granted granted Critical
Publication of JP7767651B2 publication Critical patent/JP7767651B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024566219A 2022-05-11 2023-05-10 Ｇｌｐ１医薬組成物 Active JP7767651B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263340591P 2022-05-11 2022-05-11
US63/340,591 2022-05-11
PCT/US2023/021637 WO2023220109A1 (en) 2022-05-11 2023-05-10 Glp1 pharmaceutical compositions

Publications (3)

Publication Number Publication Date
JP2025515706A JP2025515706A (ja) 2025-05-20
JPWO2023220109A5 true JPWO2023220109A5 (enExample) 2025-06-18
JP7767651B2 JP7767651B2 (ja) 2025-11-11

Family

ID=86732348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566219A Active JP7767651B2 (ja) 2022-05-11 2023-05-10 Ｇｌｐ１医薬組成物

Country Status (16)

Country Link
US (1) US20250302809A1 (enExample)
EP (1) EP4522129A1 (enExample)
JP (1) JP7767651B2 (enExample)
KR (1) KR20250002778A (enExample)
CN (1) CN119173255A (enExample)
AR (1) AR129296A1 (enExample)
AU (1) AU2023269995A1 (enExample)
CA (1) CA3253043A1 (enExample)
CL (1) CL2024003392A1 (enExample)
CO (1) CO2024015285A2 (enExample)
DO (1) DOP2024000232A (enExample)
IL (1) IL316629A (enExample)
MX (1) MX2024013839A (enExample)
PE (1) PE20251285A1 (enExample)
TW (2) TWI867526B (enExample)
WO (1) WO2023220109A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025057134A2 (en) 2023-09-14 2025-03-20 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025108361A1 (zh) * 2023-11-21 2025-05-30 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
WO2002064132A2 (en) * 2001-01-18 2002-08-22 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
AU2007293032A1 (en) * 2006-09-08 2008-03-13 Merck Sharp & Dohme Corp. Liquid pharmaceutical formulations for oral administration of a CGRP antagonist
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
JP7461104B2 (ja) 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
MA56226A (fr) 2018-12-07 2022-04-20 Neurocrine Biosciences Inc Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
SMT202500315T1 (it) 2020-09-09 2025-11-10 Crinetics Pharmaceuticals Inc Formulazioni di un modulatore della somatostatina
WO2023220112A1 (en) 2022-05-11 2023-11-16 Eli Lilly And Company Glp1 tablet compositions

Similar Documents

Publication Publication Date Title
IL316629A (en) GLP1 drug compounds
TWI405574B (zh) 藥學固體製劑及其製造方法
JP2010209104A5 (enExample)
KR102072618B1 (ko) 서방성 토피라메이트 캡슐
IL316478A (en) GLP1 tablet preparations
CN102091051A (zh) 一种别嘌醇双释放制剂及其制备方法
TW201414508A (zh) 含５－氯－ｎ－（｛（５ｓ）－２－側氧－３－［４－（３－側氧－４－嗎啉基）苯基］－１，３－□唑啶－５－基｝甲基）－２－噻吩甲醯胺之醫藥投遞型式
JP5988963B2 (ja) ピタバスタチン含有製剤及びその製造方法
JP2017088609A (ja) アンギオテンシンｉｉ拮抗作用を有する化合物を含有する固形医薬組成物
JP2017071605A5 (enExample)
JPWO2006118017A1 (ja) 安定化組成物
JP5211040B2 (ja) ピリジルメチルスルフィニルベンズイミダゾールのための経口速放医薬製剤
JP2018118966A (ja) ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
CN101626755A (zh) 包含酸不稳定药物的双单元片剂
JP2018118966A5 (enExample)
JPWO2023220109A5 (enExample)
JPH0692849A (ja) フラン誘導体を含有する医薬組成物
CN102026626A (zh) 包含草酸艾司西酞普兰的颗粒
JP6188091B2 (ja) メドキソミル基を有するプロドラッグを含有するフィルムコーティング製剤
CN101756981B (zh) 一种布洛氯雷伪麻缓释制剂及其制备方法
EP4337175A1 (en) Pharmaceutical formulation of valsartan and sacubitril
RO132297A2 (ro) Compoziţie cu cefpodoxim proxetil cu eliberare extinsă
CA3145459A1 (en) Pharmaceutical composition of darolutamide
JP6903252B2 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
JPWO2022031666A5 (enExample)